tbResList Print — PSO Psoralidin

Filters: qv=389, qv2=%, rfv=%

Product

PSO Psoralidin
Description: <b>Psoralidin<b> is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug.<br>
Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells.<br>
<pre>
Reported effects (context-dependent, preclinical):
-DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3)
-UPREGULATES apoptotic signaling (caspase activation)
-MODULATES androgen receptor signaling in prostate cancer models
-SENSITIZES tumor cells to chemo- and radio-induced stress

This positions psoralidin as a biologic modulator, not a driver.

Across cancer cell and animal models, psoralidin has been associated with:
-Apoptosis induction
-Caspase activation
-Mitochondrial depolarization
-Inflammatory pathway suppression
-NF-κB inhibition
-STAT3 attenuation
-Hormone signaling modulation
-Androgen receptor suppression (prostate cancer context)
-Oxidative stress interaction
-Redox imbalance tipping tumor cells toward death under stress

Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective
</pre>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress

Ferroptosis↑, 1,   GPx4↓, 1,   mt-ROS↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics

MMP↓, 2,  

Core Metabolism/Glycolysis

ACSL4↑, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 3,   DR5↑, 1,   Ferroptosis↑, 1,   cl‑GSDME↑, 1,   Pyro↑, 1,   TRAIL⇅, 1,   TRAIL↑, 1,   TRAILR↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 2,  

DNA Damage & Repair

P53↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

CSCs↓, 3,   EMT↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   TumCG↓, 2,  

Migration

CD31↓, 1,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling

IL18↑, 1,   IL1β↑, 1,   NF-kB↓, 2,   NK cell↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 2,   eff↑, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers

Ki-67↓, 1,  

Functional Outcomes

AntiCan↑, 1,   AntiTum↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   toxicity↓, 1,  

Infection & Microbiome

Sepsis↓, 1,  
Total Targets: 53

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis

LDH↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Clinical Biomarkers

LDH↓, 1,  

Functional Outcomes

AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome

Bacteria↓, 1,  
Total Targets: 10

Research papers

Year Title Authors PMID Link Flag
2023Targeting Breast Cancer Stem CellsLu ZhangPMC9830502https://pmc.ncbi.nlm.nih.gov/articles/PMC9830502/0
2025The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosisLing YaoPMC12584398https://pmc.ncbi.nlm.nih.gov/articles/PMC12584398/0
2025Psoralidin induces pyroptosis in both tumor cells and macrophages as well as enhances nature killer cell cytotoxicity to suppress hepatocellular carcinomaXianling Wanghttps://www.sciencedirect.com/science/article/abs/pii/S01615890250014030
2025Psoralidin's Anti-Cancer Mechanisms: A Technical GuideBenchChemhttps://pdf.benchchem.com/1678/Psoralidin_s_Anti_Cancer_Mechanisms_A_Technical_Guide.pdf0
2024Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancerTanya Tripathihttps://www.explorationpub.com/Journals/eds/Article/1008630
2012The Coumarin Psoralidin Enhances Anticancer Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Joanna BronikowskaPMC6268812https://pmc.ncbi.nlm.nih.gov/articles/PMC6268812/0